Post-acute health care utilization after SARS-CoV-2 infection: A retrospective cohort study of long COVID among 530,892 adults

Supplemental Materials

Figure E1. Cohort Construction

Figure E2: Among individuals at the 95th percentile of health care utilization, additional health care encounters (95% CI) per person-year total and by type of health care encounter, comparing individuals with a positive SARS-CoV-2 PCR test to matched individuals with negative PCR: (A) overall (n=530,232), (B) women (n=271,346), and (C) men (n=258,886).

Table E1. ICES Databases

Table E2. Variables included in the propensity score for matching

Table E3. Unmatched cohort baseline characteristics

Table E4. Distribution of baseline healthcare use by counts and rates (per person-year) for the matched cohort (n= 530,232), overall and stratified by sex.

Table E5: Sensitivity analyses: (A) Follow-up begins after hospital discharge or 56 days, whichever occurred later, (B) follow-up censored on the date of entrance to long-term care, (C) follow-up censored at 6 months, and (D) matched by intensive care admission within two weeks after index date. All comparisons are for test-positive versus test-negative individuals. Distribution of follow-up time included for each analysis. Healthcare utilization rates reported per person-year. The difference in overall healthcare utilization rates between test-positive and negative individuals are reported for the mean, 95th percentile, and 99th percentile. Samples sizes as noted below.

Figure E1: Cohort construction






Figure E2: Among individuals at the 95th percentile of health care utilization, additional health care encounters (95% CI) per person-year total and by type of health care encounter, comparing individuals with a positive SARS-CoV-2 PCR test to matched individuals with negative PCR: (A) overall (n=530,232), (B) women (n=271,346), and (C) men (n=258,886).








Table E1. ICES Databases

The following datasets were used for cohort construction, among others (Table E1): OHIP (contains all physician billing claims); the Registered Persons Database (maintains vital statistics, including out-of-hospital deaths); the Ontario Laboratories Information System (contains all PCR results for SARS-CoV-2 and was linked to the COVID19 database, which records all SARS-CoV-2 vaccinations); the Canadian Institute for Health Information Discharge Abstract Database (records all hospitalizations in Ontario); the National Ambulatory Care Reporting System (includes all emergency department visits in Ontario); and the Ministry of Health and Long-Term Care (MOHLTC; residence in long-term care).

CIHI	NRS	HCD	CENSUS	INST	ODD
OHIP	ODB	RAICA	LIHN	ASTHMA	DEMENTIA
NACRS	CCRS	IPDB	REF	HYPER	COPD
SDS	CONTACT	CPDP	PCCF	HIV	ORAD
OHMRS	RAIHC	RPDB	DIN	CHF	OCCC
ODD	CCN	OCR	CDFP	ADP	ERCLAIM
AVGPRICE	ORGD	ETHNIC	Getacg	ESTSOB	GAPP
ONMARG	CCM	C19INTGR	DAD	COVAXON	OLIS
CAPE	NMS	OCCI	OHCAS		

Table E2. Variables included in the propensity score for matching*

* also used for hard matching

* also used for hard ma	
Variable	Definition and/or source
Sex*	Male, female
Week of outbreak*	Index date January 28, 2020; two-week blocks
Hospitalization*	On or within 2 weeks after the index date
Public health unit	OMHRS, DAD
(PHU)*	
Age	Years, restricted cubic spline
Neighbourhood	RPDB, PCCF
income quintile	
Residential instability	ONMARG quintiles
Material deprivation	ONMARG quintiles
Dependency	ONMARG quintiles
Ethnic concentration	ONMARG quintiles
Rurality	RPDB, PCCF
Week of outbreak	Index date January 28, 2020; two-week blocks
Diabetes	ODD_sensitive
Pregnancy	MOMBABY ¹⁻⁴
Hypertension	HYPER
Acute myocardial	≥1 DAD ICD10: I21, I22, I25.2
infarction	
Percutaneous	CIHI DAD/SDS: CCP: 48.02, 48.09; CCI: 1IJ50, 1IJ57GQ 1IJ80, 1IJ26, 1IJ54,
coronary intervention	1IJ55; OHIP: Z434, Z448, Z449, Z460, Z461
Coronary artery	(CIHI DAD/SDS): CCI 1IJ76; CCP 48.1, 48.2; OHIP R742, R743
bypass surgery	
Ischemic stroke	One DAD, 2 OHIP, or 1 NACRS&10HIP: ICD-10 codes I63, I64, H341 (excluding
	I63.6) as ANY diagnosis type, exclude suspect; ICD-9 code 434, 436 for OHIP
Hemorrhagic stroke	1 record in DAD or NACRS: ICD-10 I60, I61; ICD-9 430, 431
Major bleeding event	ICD 10:
	GI: 1850, 1983, K250/252/254/256, K260/262/264/266, K270/272/274/276,
	K280/282/284/286, K290, K661, K920, K921, K922
	ICH: I60, I61, I620, I621, I629
	GU: N020-029, R310,R311, R318
	Resp: R040, R041, R042, R048, R049
	Other: R58, D68.3, H35.6, H45.0, M25.0

Solid cancer, hematologic cancer	OCR: OCR_TOPOG_	CD, OCR_DIAG_DATE						
Same-day surgery in prior 6 weeks	SDS_ADMDATE, SDS	S_INCODE1-10, SDS_CACSANETECH						
Valvular disease	ICD9: 394, 395, 396							
valvulai disease		100 1000 1040 1040						
		, 108, 1099, 1342, 1348, 1349						
		d CCI codes 1HS90LACF, 1HT90LACF, 1HU90DACF,						
	1HU90LACF, 1HU90F	PNCF, 1HV90LACF, 1HV90LACFA, 1HV90LACFL,						
	1HV90LACFN, 1HV90)WJCFN						
Emphysema	COPD_SPECIFIC in C							
Asthma	ASTHMA SPEC in AS							
	_	STITIVIA database						
Atrial fibrillation	Any of the following:							
		ion (CIHI DAD) ⁵ : ICD9 427.3 or ICD10 I48 as any diagnosis						
	type, including suspec							
	-history of ED visit with							
	-4 OHIP claims in 1 ye	ear (OHIP) dxcode 427						
Heart failure	CHF database							
Ischemic heart	PCL CABG. (1 HOSP	in DAD with any codes I20-I25) or (2 OHIP billings within a						
disease	one-year period with d	, ,						
Renal disease		les E102, E112, E132, E142, I12, I13, N01.*, N03.*, N05.*,						
ixerial disease	N08.*, N18.*, N19.*, N							
		120.						
	or . D. I . (A	0 ''': 00 (
		2 codes within 90 days of one another):						
		323, G325, G326, G330, G331, G860, G333, G083, G091,						
		090, G092, G093, G094, G861, G862, G863, G864, G865,						
	G866, G294, G095, G	096 CCP: 51.95, 66.98						
	NACRS: CCI: 1PZ21F	IQBR, 1PZ21HPD4						
Pneumonia	(CIHI DAD, NACRS, OHIP) – ICD-10 codes J10.0, J11.0 or J12-J18 as ANY							
	diagnosis type, exclude suspected ⁶ ; OHIP dxcode 486, excluding claims							
		ides G538, G539, G840-G848, G590, G591 or G700						
Demontis	(administration of vaccinations) (1 DAD or 3 OHIP billings separated by 30 days, within a 2-year period or any							
Dementia								
	cholinesterase inhibito							
		, F051, G30, G31, R54						
	ICD9 code 290, 294, 3							
		NESTERASE INHIBITORS						
		ntamine, or rivastigmine (DIN: 02232043, 02232044,						
	02269457, 02269465,	02244298, 02244299, 02244300, 02244302, 02266717,						
	02266725) or Tacrine	(Cognex) (DIN: 66123288, 66123290, 66123306, 66123318)						
Alcohol substance		F1029, F1019, F1099, F10250, F10150, F10950, F10920,						
use disorder		251, F10151, F10951, F1027, F1097, F1026, F1096,						
400 4.001401		10, F1021, F1020, F10220, F10229						
	ICD9 codes 291, 303	10,1 1021,1 1020,1 10220,1 10220						
Johns Hopkins ACG		HIP, NACRS-ED, CIHI DAD)						
•	Julii Oi ADGS (IIOIII O	TIII, NAUNO-ED, UITII DAD)						
score	(OLUB NAODO 55 0)	III DAD)						
John Hopkins frailty	(OHIP, NACRS-ED CI	HI DAD)						
indicator								
Influenza vaccination		cination (OHIP, ODB) – Received between Sep 1, 2019 and						
		algorithm in Concept Dictionary and attached MOHLTC						
	bulletin (pdf) for public	cally funded DINs for 2019-20 season. Note: algorithm does						
	not capture vaccinatio	ns received outside doctor's offices and pharmacies						
Venous	CIHI-NACRS, DAD, O							
thromboembolism	ICD-10 Code	Description						
		DX10CODE1 in NACRS, DX10CODE1-10 in DAD						
	126.*	Pulmonary embolism						
	126.0	Pulmonary embolism with mention of acute cor pulmonale						
	126.9	Pulmonary embolism without mention of acute cor						
	120.3	pulmonale						
	100 *	<u> </u>						
	180.*	Phlebitis and thrombophlebitis ^T						
	180.1	Phlebitis and thrombophlebitis of femoral vein						
	180.2	Phlebitis and thrombophlebitis of other deep vessels of						

5,
ower
. I82.3:
3

Supplemental Material References

- Aoyama K, Ray JG, Pinto R, et al. Temporal Variations in Incidence andOutcomes of Critical Illness Among Pregnant and Postpartum Women inCanada: A Population-Based Observational Study. J Obstet Gynaecol Can. 2019;41(5):631-640.
- Metcalfe A, Lix LM, Johnson JA, et al. Validation of an obstetric comorbidity index in an external population. BJOG. 2015;122(13):1748-1755.
- 3. Joseph KS, Fahey J, Canadian Perinatal Surveillance S. Validation of perinatal data in the Discharge Abstract Database of the Canadian Institute for Health Information. *Chronic Dis Can.* 2009;29(3):96-100.
- 4. Samiedaluie S, Peterson S, Brant R, Kaczorowski J, Norman WV. Validating abortion procedure coding in Canadian administrative databases. *BMC Health Serv Res.* 2016;16:255.
- 5. Tu K, Nieuwlaat R, Cheng SY, et al. Identifying Patients With Atrial Fibrillation in Administrative Data. *Can J Cardiol.* 2016;32(12):1561-1565.
- 6. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. *N Engl J Med.* 2013;369(2):155-163.
- 7. MHASEF Research Team. Mental Health and Addictions System Performance in Ontario: A Baseline Scorecard. Toronto, ON: Institute for Clinical Evaluative Sciences; 2018. Available from: https://www.ices.on.ca/Publications/Atlases-and-Reports/2018/MHASEF.
- 8. MHASEF Research Team. The Mental Health of Children and Youth in Ontario: 2017 Scorecard. Toronto, ON: Institute for Clinical Evaluative Sciences; 2017. ISBN: 978-1-926850-72-6. Available

from: https://www.ices.on.ca/Publications/Atlases-and-Reports/2017/MHASEF.

9. ICES Data Dictionary.

https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx. Last accessed February 11, 2022.

Table E3: Unmatched cohort, baseline characteristics

		Negative SARS- CoV-2 PCR	Positive SARS-CoV- 2 PCR	Total	
VARIABLE		N=3,362,519	N=268,521	N=3,631,040	Standardized Difference
Age, years	Mean ± SD	46.77 ± 18.17	44.18 ± 17.18	46.58 ± 18.11	0.15
	Median (IQR)	45 (31-60)	43 (29-56)	45 (31-60)	0.14
Women, n (%)		1,864,241 (55.4%)	137,245 (51.1%)	2,001,486 (55.1%)	0.09
Income Quintile, n (%)	Missing	10,050 (0.3%)	774 (0.3%)	10,824 (0.3%)	0
	1	630,532 (18.8%)	66,584 (24.8%)	697,116 (19.2%)	0.15
	2	649,204 (19.3%)	58,115 (21.6%)	707,319 (19.5%)	0.06
	3	672,162 (20.0%)	57,233 (21.3%)	729,395 (20.1%)	0.03
	4	684,228 (20.3%)	47,450 (17.7%)	731,678 (20.2%)	0.07
	5	716,343 (21.3%)	38,365 (14.3%)	754,708 (20.8%)	0.18
Instability Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	691,223 (20.6%)	72,327 (26.9%)	763,550 (21.0%)	0.15
	2	626,597 (18.6%)	44,606 (16.6%)	671,203 (18.5%)	0.05
	3	610,179 (18.1%)	40,798 (15.2%)	650,977 (17.9%)	0.08
	4	610,967 (18.2%)	43,693 (16.3%)	654,660 (18.0%)	0.05
	5	786,188 (23.4%)	65,034 (24.2%)	851,222 (23.4%)	0.02
Deprivation Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	802,901 (23.9%)	45,106 (16.8%)	848,007 (23.4%)	0.18
	2	708,278 (21.1%)	47,637 (17.7%)	755,915 (20.8%)	0.08
	3	632,209 (18.8%)	52,504 (19.6%)	684,713 (18.9%)	0.02
	4	594,666 (17.7%)	55,590 (20.7%)	650,256 (17.9%)	0.08
	5	587,100 (17.5%)	65,621 (24.4%)	652,721 (18.0%)	0.17
Dependency Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	901,394 (26.8%)	91,929 (34.2%)	993,323 (27.4%)	0.16
	2	671,373 (20.0%)	59,930 (22.3%)	731,303 (20.1%)	0.06
	3	582,059 (17.3%)	44,238 (16.5%)	626,297 (17.2%)	0.02
	4	557,097 (16.6%)	37,506 (14.0%)	594,603 (16.4%)	0.07
	5	613,231 (18.2%)	32,855 (12.2%)	646,086 (17.8%)	0.17
Ethnic Concentration	Minning	27 205 (4 40/)	0.000 (0.00()	20 420 (4 40/)	0.04
Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	535,172 (15.9%) 579,980 (17.2%)	17,294 (6.4%) 24,901 (9.3%)	552,466 (15.2%) 604,881 (16.7%)	0.3
	2 3	635,538 (18.9%)	35,134 (13.1%)	670,672 (18.5%)	0.24 0.16
	4	726,900 (21.6%)	57,068 (21.3%)	783,968 (21.6%)	0.10
	5	847,564 (25.2%)	132,061 (49.2%)	979,625 (27.0%)	0.51
Rural, n (%)	Missing	8,780 (0.3%)	671 (0.2%)	9,451 (0.3%)	0.51
Ruiai, ii (70)	iviissiiig	339,985 (10.1%)	10,538 (3.9%)	350,523 (9.7%)	0.24
Pandemic Quarter	2020-Q1	19,479 (0.6%)	3,457 (1.3%)	22,936 (0.6%)	0.24
Pandemic Quarter	2020-Q1 2020-Q2	297,938 (8.9%)	21,179 (7.9%)	319,117 (8.8%)	0.07
	2020-Q2 2020-Q3	686,688 (20.4%)	14,775 (5.5%)	701,463 (19.3%)	0.04
	2020-Q3 2020-Q4	972,169 (28.9%)	104,177 (38.8%)	1,076,346 (29.6%)	0.40
	2020-Q4 2021-Q1	1,386,245 (41.2%)	124,933 (46.5%)	1,511,178 (41.6%)	0.21
Received 2 vaccine doses,	2021-01	1,000,240 (41.270)	124,300 (40.070)	1,511,170 (41.070)	0.11
n (%) Received 1 vaccine dose, n		71,870 (2.1%)	300 (0.1%)	72,170 (2.0%)	0.19
(%) Received 0 vaccine doses,		78,444 (2.3%)	1,403 (0.5%)	79,847 (2.2%)	0.15
n (%)		3,212,205 (95.5%)	266,818 (99.4%)	3,479,023 (95.8%)	0.25

Aggregated diagnosis group	Mean ± SD	5.82 ± 3.80	5.59 ± 3.69	5.81 ± 3.79	0.06
group	Median (IQR)	5 (3-8)	5 (3-8)	5 (3-8)	0.06
Hospital Frailty Risk Score	Mean ± SD	2.42 ± 4.76	2.40 ± 5.03	2.42 ± 4.78	0.00
Hospital Franty Risk Goorg	Median (IQR)	0 (0-3)	0 (0-2)	0 (0-3)	0.06
Hospitalizations in prior	Wedian (rent)	0 (0 0)	0 (0 2)	0 (0 0)	0.00
year	Mean ± SD	0.10 ± 0.45	0.07 ± 0.39	0.10 ± 0.44	0.07
	Median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	0.09
Clinic visits in prior year	Mean ± SD	6.56 ± 8.35	6.27 ± 7.86	6.54 ± 8.32	0.04
Homogoro vigito in prior	Median (IQR)	4 (1-9)	4 (1-9)	4 (1-9)	0.03
Homecare visits in prior year	Mean ± SD	3.10 ± 25.71	2.92 ± 26.23	3.09 ± 25.75	0.01
,	Median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	0.07
ED visits in prior year	Mean ± SD	0.50 ± 1.45	0.41 ± 1.42	0.49 ± 1.45	0.06
, ,	Median (IQR)	0 (0-1)	0 (0-0)	0 (0-1)	0.08
Days hospitalized in prior					
year	Mean ± SD	1.02 ± 6.85	0.83 ± 7.88	1.00 ± 6.93	0.03
Hospitalized within 2	Median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	0.15
weeks, n (%)		246,238 (7.3%)	14,942 (5.6%)	261,180 (7.2%)	0.07
Admitted to intensive care		04 000 (0 00()	0.000 (4.40()	0.4.00.4.40.00(.)	0.00
unit within 2 weeks, n (%) Johns Hopkins Frailty		31,068 (0.9%)	2,933 (1.1%)	34,001 (0.9%)	0.02
Index, n (%)		116,104 (3.5%)	7,895 (2.9%)	123,999 (3.4%)	0.03
Flu vaccine within prior		1 064 549 (24 70/)	66 254 (24 70/)	1 120 060 (21 10/)	0.15
year, n (%)		1,064,518 (31.7%) 29,558 (0.9%)	66,351 (24.7%) 1,855 (0.7%)	1,130,869 (31.1%)	0.15 0.02
Pregnancy, n (%)		•	61,708 (23.0%)	31,413 (0.9%)	0.02
Hypertension, n (%)		816,144 (24.3%)		877,852 (24.2%)	
Diabetes, n (%)		395,575 (11.8%) 93,686 (2.8%)	37,775 (14.1%)	433,350 (11.9%)	0.07
Emphysema, n (%) Heart failure, n (%)		88,669 (2.6%)	4,138 (1.5%) 4,994 (1.9%)	97,824 (2.7%) 93,663 (2.6%)	0.09 0.05
					0.03
Dementia, n (%) Asthma, n (%)		42,410 (1.3%) 414,612 (12.3%)	3,274 (1.2%) 28,270 (10.5%)	45,684 (1.3%) 442,882 (12.2%)	0.06
Cancer, n (%)		112,188 (3.3%)	4,809 (1.8%)	116,997 (3.2%)	0.00
Surgery in prior 6 weeks, n		112,100 (3.370)	4,009 (1.070)	110,997 (3.270)	0.1
(%)		57,709 (1.7%)	2,215 (0.8%)	59,924 (1.7%)	0.08
Ischemic stroke, n (%)		42,908 (1.3%)	2,547 (0.9%)	45,455 (1.3%)	0.03
Hemorrhagic stroke, n (%)		3,533 (0.1%)	224 (0.1%)	3,757 (0.1%)	0.01
Valvular disease, n (%)		4,609 (0.1%)	235 (0.1%)	4,844 (0.1%)	0.01
Atrial fibrillation, n (%)		93,557 (2.8%)	4,896 (1.8%)	98,453 (2.7%)	0.06
Myocardial infarction, n (%)		33,446 (1.0%)	1,801 (0.7%)	35,247 (1.0%)	0.04
Percutaneous coronary inter	vention, n (%)	39,373 (1.2%)	2,231 (0.8%)	41,604 (1.1%)	0.03
Coronary artery bypass, n (%)		11,845 (0.4%)	648 (0.2%)	12,493 (0.3%)	0.02
Ischemic heart disease, n					
(%)		167,514 (5.0%)	9,846 (3.7%)	177,360 (4.9%)	0.06
Major bleeding, n (%)		37,210 (1.1%)	2,156 (0.8%)	39,366 (1.1%)	0.03
Renal disease, n (%)		43,949 (1.3%)	2,779 (1.0%)	46,728 (1.3%)	0.03
Pneumonia, n (%)		271,036 (8.1%)	20,166 (7.5%)	291,202 (8.0%)	0.02
Alcohol use disorder, n (%) Venous thromboembolism,		27,759 (0.8%)	1,668 (0.6%)	29,427 (0.8%)	0.02
n (%)		396,371 (11.8%)	24,085 (9.0%)	420,456 (11.6%)	0.09
Mental health hospitalization	, n (%)	77,945 (2.3%)	4,470 (1.7%)	82,415 (2.3%)	0.05
Mental health emergency vis		188,832 (5.6%)	11,469 (4.3%)	200,301 (5.5%)	0.06
Mental health clinic visit, n					
(%)	(0/)	747,646 (22.2%)	48,712 (18.1%)	796,358 (21.9%)	0.1
Hospital mental health diagno	oses, no. (%)				0

Substance use disorder	19,681 (0.6%)	1,138 (0.4%)	20,819 (0.6%)	0.02
Dementia/Alzheimer's	2,034 (0.1%)	193 (0.1%)	2,227 (0.1%)	0
Delirium	5,696 (0.2%)	423 (0.2%)	6,119 (0.2%)	0
Anxiety	4,340 (0.1%)	203 (0.1%)	4,543 (0.1%)	0.02
Deliberate self-harm	5,492 (0.2%)	354 (0.1%)	5,846 (0.2%)	0.01
Schizophrenia	14,352 (0.4%)	937 (0.3%)	15,289 (0.4%)	0.01
Mood disorders	636 (0.0%)	23 (0.0%)	659 (0.0%)	0.01
Mood disorder - bipolar	8,380 (0.2%)	417 (0.2%)	8,797 (0.2%)	0.02
Mood disorder - depression	21,114 (0.6%)	1,015 (0.4%)	22,129 (0.6%)	0.04
Mood disorder - other	347 (0.0%)	12 (0.0%)	359 (0.0%)	0.01
Personality disorders	5,683 (0.2%)	234 (0.1%)	5,917 (0.2%)	0.02
Nonclassified Trauma/stress related	4,919 (0.1%)	302 (0.1%)	5,221 (0.1%)	0.01
disorders Obsessive compulsive	9,008 (0.3%)	443 (0.2%)	9,451 (0.3%)	0.02
disorder	465 (0.0%)	26 (0.0%)	491 (0.0%)	0
Eating disorder	854 (0.0%)	37 (0.0%)	891 (0.0%)	0.01
Emergency department mental health diagnoses				
Substance use disorder	60,371 (1.8%)	4,178 (1.6%)	64,549 (1.8%)	0.02
Dementia/Alzheimer's	1,971 (0.1%)	158 (0.1%)	2,129 (0.1%)	0
Delirium	1,195 (0.0%)	72 (0.0%)	1,267 (0.0%)	0
Anxiety	68,125 (2.0%)	3,872 (1.4%)	71,997 (2.0%)	0.04
Deliberate self-harm	16,222 (0.5%)	1,057 (0.4%)	17,279 (0.5%)	0.01
Schizophrenia	11,013 (0.3%)	745 (0.3%)	11,758 (0.3%)	0.01
Bipolar	5,640 (0.2%)	262 (0.1%)	5,902 (0.2%)	0.02
Depression	34,030 (1.0%)	1,778 (0.7%)	35,808 (1.0%)	0.04
Other	2,265 (0.1%)	108 (0.0%)	2,373 (0.1%)	0.01
Personality disorders	8,318 (0.2%)	446 (0.2%)	8,764 (0.2%)	0.02
Nonclassified Trauma/stress related	6,950 (0.2%)	473 (0.2%)	7,423 (0.2%)	0.01
disorders Obsessive compulsive	41,958 (1.2%)	2,202 (0.8%)	44,160 (1.2%)	0.04
disorder	626 (0.0%)	39 (0.0%)	665 (0.0%)	0
Eating disorder	614 (0.0%)	22 (0.0%)	636 (0.0%)	0.01
Outpatient OHIP mental health diagnosis codes,	no. (%)			
Psychotic disorders	43,698 (1.3%)	3,137 (1.2%)	46,835 (1.3%)	0.01
Mood and anxiety disorders	385,325 (11.5%)	22,799 (8.5%)	408,124 (11.2%)	0.1
Substance use disorders	110,162 (3.3%)	6,198 (2.3%)	116,360 (3.2%)	0.06
Non-psychotic disorders	190,835 (5.7%)	12,795 (4.8%)	203,630 (5.6%)	0.04
Social problems	127,299 (3.8%)	8,967 (3.3%)	136,266 (3.8%)	0.02
Other	139,737 (4.2%)	9,465 (3.5%)	149,202 (4.1%)	0.03

Table E4: Distribution of <u>baseline healthcare utilization rates (per person-year)</u> for the matched cohort (n= 530,232), overall and stratified by sex.

Rate of baseline healthcare SARS-CoVutilization (previous year; per 2 PCR Test Result std Q1 Median Q3 p95 p99 person year) Mean Overall Outpatient clinical encounters Negative 6.3 7.9 1.0 4.0 8.0 21.0 37.0 Positive 6.3 7.8 1.0 4.0 8.0 21.0 36.0 Homecare encounters Negative 2.7 0.0 0.0 0.0 91.1 25.0 0.0 Positive 2.8 25.7 0.0 0.0 0.0 0.0 95.1 Emergency department visits Negative 0.4 1.2 0.0 0.0 0.0 2.0 4.0 Positive 0.4 1.4 0.0 0.0 0.0 2.0 4.0 Days hospitalized 0.0 2.0 Negative 8.0 6.9 0.0 0.0 17.0 Positive 8.0 7.3 0.0 0.0 0.0 2.0 17.0 Total healthcare utilization Negative 10.2 29.5 1.0 4.0 10.0 29.0 131.1 Positive 10.3 30.3 1.0 4.0 10.0 28.0 137.1 Women (n=271,346) Outpatient clinical encounters Negative 7.2 8.3 2.0 5.0 10.0 23.0 38.0 Positive 8.2 2.0 5.0 10.0 23.0 38.0 7.3 Homecare encounters Negative 26.8 0.0 0.0 104.1 3.1 0.0 0.0 Positive 29.4 0.0 132.1 3.5 0.0 0.0 0.0 Emergency department visits Negative 0.4 1.1 0.0 0.0 0.0 2.0 4.0 Positive 0.4 1.2 0.0 0.0 0.0 2.0 4.0 Days hospitalized Negative 0.7 6.2 0.0 0.0 0.0 2.0 15.0 Positive 6.4 2.0 8.0 0.0 0.0 0.0 16.0 Men (n=258,886) 7.4 7.0 Outpatient clinical encounters Negative 5.3 1.0 3.0 19.0 35.0 Positive 5.2 7.4 1.0 3.0 7.0 18.0 34.0 Homecare encounters Negative 2.4 22.8 0.0 0.0 0.0 0.0 68.0 Positive 2.0 21.1 0.0 0.0 0.0 0.0 50.0 Negative 2.0 4.0 Emergency department visits 0.4 1.2 0.0 0.0 0.0 4.0 Positive 0.4 1.5 0.0 0.0 0.0 2.0 Days hospitalized Negative 0.9 7.6 0.0 0.0 0.0 2.0 20.0 Positive 8.0 8.1 0.0 0.0 0.0 1.0 18.0

Table E5: Sensitivity analyses: (A) Follow-up begins after hospital discharge or 56 days, whichever occurred later, (B) follow-up censored on the date of entrance to long-term care, (C) follow-up censored at 6 months, and (D) matched by intensive care admission within two weeks after index date. All comparisons are for test-positive versus test-negative individuals. Distribution of follow-up time included for each analysis. Healthcare utilization rates reported per person-year. The difference in overall healthcare utilization rates between test-positive and negative individuals are reported for the mean, 95th percentile, and 99th percentile. Samples sizes as noted below.

Rates (per person-year)	SARS-CoV- 2 Positive PCR Test Result	Mean	std	∆ for mean	Q1	Median	Q3	p95	p99	Δ for 95th percentile	Δ for 99th percentile
Sensitivity analysis								<u> </u>	<u> </u>	p	p 01 0 0 11 0 11 0 11 0 11 0 11 0 11 0
Total healthcare											
utilization	Negative	12.8	40.5		1.2	4.5	10.7	34.5	264.4		
	Positive	14.2	45.1	1.3	1.4	4.9	11.3	36.4	335.4	1.8	71.0
Outpatient clinical	Negative	7.1	10.6		0.0	4.0	9.5	24.7	45.1		
encounters	Negative			0.0						0.0	0.4
Homecare	Positive	7.4	11.2	0.3	1.0	4.4	10.1	25.2	45.0	0.6	-0.1
encounters	Negative	4.1	32.4		0.0	0.0	0.0	0.0	167.4		
	Positive	4.2	32.5	0.0	0.0	0.0	0.0	0.0	169.6	0.0	2.2
Emergency											
department visits	Negative	0.4	1.5		0.0	0.0	0.0	2.5	5.4		
	Positive	0.4	1.7	0.0	0.0	0.0	0.0	2.4	5.5	0.0	0.1
Days hospitalized	Negative	0.7	8.3		0.0	0.0	0.0	1.7	13.8		
	Positive	1.0	11.7	0.3	0.0	0.0	0.0	1.8	16.0	0.1	2.2
Days in long-term											
care	Negative	0.5	11.6		0.0	0.0	0.0	0.0	0.0		
	Positive	1.2	19.2	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Follow-up (days)	Negative	240	87		187	221	267	457	495		
	Positive	240	87		188	221	267	457	494		
Sensitivity analysis	(B): Follow-up c	ensored a	t entrand	ce to long-	term c	are (n=530	,232)				
Rates (per person- year)		Mean	std	Δ for mean	Q1	Median	Q3	p95	p99	Δ for 95th percentile	Δ for 99th percentile
Total healthcare	N. C	40.5	00.0		4.0	4.5	40.7	0.4.0	040.5		
utilization	Negative	12.5	39.2	4.4	1.2	4.5	10.7	34.2	243.5	4 =	540
Outpatient clinical	Positive	13.6	42.5	1.1	1.4	4.9	11.2	35.7	297.5	1.5	54.0
encounters	Negative	7.1	10.4		0.0	4.0	9.6	24.7	45.2		
0.1.000	Positive	7.4	10.7	0.3	1.0	4.4	10.1	25.4	45.2	0.7	0.0
Homecare				0.0							0.0
encounters	Negative	4.2	32.8		0.0	0.0	0.0	0.0	172.1		
	Positive	4.3	33.3	0.1	0.0	0.0	0.0	0.0	182.6	0.0	10.5
Emergency											
department visits	Negative	0.4	1.5		0.0	0.0	0.0	2.5	5.4		
	Positive	0.4	1.7	0.0	0.0	0.0	0.0	2.4	5.5	0.0	0.1
Days hospitalized	Negative	0.8	10.1		0.0	0.0	0.0	1.7	14.5		
	Positive	1.5	16.7	0.6	0.0	0.0	0.0	1.9	22.1	0.1	7.6
Days in long-term	Negative										
care	Negative	•	•		•	•		•	•		
	Positive										
Follow-up (days)	Negative	240	87		186	221	267	457	495		
	Positive	239	88		187	220	267	457	494		
Sensitivity analysis	(C) Follow-up ce	ensored at	6 month		232)					A for 054	A for 004
Rates (per person- year) Total healthcare		Mean	std	∆ for mean	Q1	Median	Q3	p95	p99	∆ for 95th percentile	∆ for 99th percentile
utilization	Negative	12.8	40.6		0.0	4.0	10.1	35.1	264.4		
	Positive	14.3	45.0	4.4	0.0	4.0	12.1	38.3	337.0	3.2	72.6
Outpatient clinical											

	Positive	7.5	11.0	0.3	0.0	4.0	10.1	26.2	46.4	0.0	0.0
Homecare											
encounters	Negative	4.1	32.6		0.0	0.0	0.0	0.0	167.5		
	Positive	4.1	32.5	-0.1	0.0	0.0	0.0	0.0	163.5	0.0	-4.0
Emergency											
department visits	Negative	0.4	1.5		0.0	0.0	0.0	2.2	6.1		
	Positive	0.4	1.7	0.2	0.0	0.0	0.0	2.1	6.1	0.0	0.0
Days hospitalized	Negative	8.0	9.0		0.0	0.0	0.0	2.0	14.1		
	Positive	1.3	13.7	4.7	0.0	0.0	0.0	2.0	22.2	0.0	8.1
Days in long-term											
care	Negative	0.4	10.7		0.0	0.0	0.0	0.0	0.0		
	Positive	1.0	17.2	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Follow-up (days)	Negative	174	17		181	181	181	181	181		
	Positive	174	17		181	181	181	181	181		

Rates (per person-				Δ for						Δ for 95th	Δ for 99th
year)		Mean	std	mean	Q1	Median	Q3	p95	p99	percentile	percentile
Total healthcare											
utilization	Negative	12.8	40.6		1.1	4.5	10.7	34.5	268.1		
	Positive	14.1	44.6	1.3	1.4	4.9	11.2	36.2	332.5	1.7	64.4
Outpatient clinical											
encounters	Negative	7.1	10.3		0.0	4.0	9.5	24.6	45.3		
	Positive	7.4	10.6	0.3	1.0	4.4	10.0	25.2	44.9	0.6	-0.4
Homecare											
encounters	Negative	4.1	32.4		0.0	0.0	0.0	0.0	163.5		
	Positive	4.1	32.0	0.0	0.0	0.0	0.0	0.0	161.4	0.0	-2.2
Emergency											
department visits	Negative	0.4	1.5		0.0	0.0	0.0	2.5	5.4		
	Positive	0.4	1.7	0.0	0.0	0.0	0.0	2.4	5.5	0.0	0.0
Days hospitalized	Negative	0.8	8.8		0.0	0.0	0.0	1.7	13.9		
	Positive	1.1	12.4	0.4	0.0	0.0	0.0	1.8	20.1	0.1	6.2
Days in long-term				***							
care	Negative	0.5	11.7		0.0	0.0	0.0	0.0	0.0		
	Positive	1.1	18.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0